Sigachi Industries Invests $1M in Hyderabad R&D Hub for API Innovation

Sigachi Industries Limited, a prominent entity in the pharmaceutical sector, is setting up a research and development center in Hyderabad, unifying its essential API Innovation and analytical initiatives in one location. This strategic plan entails an investment of as much as US $1 million and is scheduled to start right away, strengthening Sigachi's dedication to innovation, as well as sustainable growth and efficiency.

The firm is boosting its R&D funding to promote valuable innovation and aims to support an extra 6 CEPs over the next 6 months. These strategic investments will aid in the advancement of both current and new molecules while also solidifying Sigachi’s long-term growth path, guaranteeing ongoing profitability and market dominance.

The newly established facility aims to: Enhance API production through the integration of cutting-edge systems while complying with rigorous global regulatory standards to guarantee high-quality outcomes that align with international criteria; Foster sustainable growth by broadening the company's development pipeline and speeding up R&D advancements with a committed investment of up to US $1 million; Cultivate talent by hiring a team of 15-20 proficient R&D scientists dedicated to expediting product development for regulated markets; and optimizing the pharmaceutical product portfolio to concentrate on key APIs and Intermediates.

Commenting on this development, Amit Raj Sinha, Managing Director and CEO,  Sigachi Industries Limited said, "We have made significant progress by delivering Active Pharmaceutical Ingredients (APIs) to the pharmaceutical market. Our increased commitment to R&D is a clear testament to our strategic vision for innovation and excellence. By deepening our investments in R&D, we are not only accelerating our development efforts but also reinforcing our long-term growth objectives and strengthening Sigachi’s overall pipeline.”